Abstract
Adriamycin, a broad-spectrum cytotoxic agent useful in cancer chemotherapy, is limited by a dose-dependent cardiomyopathy mediated in part by disruption of mitochondrial energetics. Hexakis(2-methoxyisobutyl isonitrile)technetium(I)(99mTc-SESTAMIBI) is a gammaemitting radiopharmaceutical with myocellular accumulation properties dependent on mitochondrial membrane potential. To test the hypothesis that99mTc-SESTAMIBI could monitor Adriamycin-induced alterations in cardiac energetics, cultured chick heart cells were treated with Adriamycin and99mTc-SESTAMIBI tracer kinetics were determined. Concentration- and time-dependent depression of99mTc-SESTAMIBI accumulation was evident within 60 min of treatment. The apparentK i for acute Adriamycin inhibition of tracer accumulation was 82 μM. After 24 h of treatment, Adriamycin concentrations as low as 0.1 μM demonstrated detectable inhibitory effects. The apparentK i for this subchronic Adriamycin inhibition of99mTc-SESTAMIBI accumulation was 18 μM. Subchronic concentration-dependent increases in adriamycin-induced myocellular injury as reflected by lactate dehydrogenase (LDH) release correlated inversely with decreases in99mTc-SESTAMIBI accumulation. These data further support a contribution from altered mitochondrial energetics to Adriamycin-induced injury and establish a pharmacological foundation for pursuing the possibility of noninvasive imaging of chronic Adriamycin cardiotoxicity in cancer patients using99mTc-SESTAMIBI.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alexander J, Daimak N, Berger HJ, et al (1979) Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278–283
Billingham ME, Mason JW, Bristow MR, et al (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865–872
Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, Holman BL, Piwnica-Worms D (1992) Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat heart. J nucl Med 33:1516–1521
Cheneval D, Muller M, Toni R, Ruetz S, Carafoli E (1985) Adriamycin as probe for the transversal distribution of cardiolipin in the inner mitochondrial membrane. J Biol Chem 260:13003–13007
Chiu ML, Kronauge JF, Piwnica-Worms D (1990) Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile)technetium(I) in cultured mouse fibroblasts. J Nucl Med 31:1646–1653
Czarnecki M (1984) Animal models of drug-induced cardiomyopathy. Comp Biochem Physiol 79:9–14
Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, et al (1990) Uptake of the cation hexakis (2-methoxy-isobutylisonitrile) technetium-99m by human carcinoma cell lines in vitro. Cancer Res 50:2198–2202
Eilers M, Endo T, Schatz G (1989) Adriamycin, a drug interacting with acid phospholipids, blocks import of precursor proteins by isolated yeast mitochondria. J Biol Chem 264:2945–2950
Estorch M, Carrio I, Berna L, et al (1990) Indium-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 31:1965–1969
Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199
Glantz SA (1987) Primer of biostatistics, 2nd edn. McGraw-Hill, New York, p 379
Goorin AM, Bonow KM, Goldman A, et al (1981) Congestive heart failure due to Adriamycin cardiotoxicity: its natural history in children. Cancer 47:2810–2816
Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert J (1990) Structure of the Adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 35:247–257
Gosalvez M, Blanco M, Hunter J, Miko M, Chance B (1974) Effects of anti-cancer agents on the respiration of isolated mitochondria and tumor cells. Eur J Cancer 10:567–574
Howell N, Belli TA, Zaczkiewics LT, Belli JA (1984) High level, unstable Adriamycin resistance in a Chinese hamster mutant cell line with double minute chromosomes. Cancer Res 44:4023–4030
Iwamoto Y, Hansen JL, Porter TH, Folkers K (1974) Inhibition of coenzyme Q10-enzymes succinoxidase and NADH oxidase by Adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun 58:633–638
Jaenke R (1974) An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest 30:292–304
Jones AG, Abrams MJ, Davison A, et al (1984) Biological studies of a new class of technetium complexes: the hexakis (alkylisonitrile) technetium(I) cations. Int J Nucl Med Biol 11:225–234
Keizer H, Pinedo H, Schuurhuis G, Joenje H (1990) Doxorubicin (Adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47:219–231
Kim DH, Landry AB, Lee YS, Katz AM (1989) Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 21:433–436
Kishi T, Watanabe T, Folkers K (1976) Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by Adriamycin of Q10-enzymes in mitochondria of the myocardium. Proc Natl Acad Sci USA 73:1653–1656
Lampidis T, Moreno G, Salet C, Vinzens F (1979) Nuclear and mitochondrial effects of Adriamycin in singly isolated pulsating myocardial cells. J Mol Cell Cardiol 11:415–422
Lamson ML, Kirscher AS, Hotte CE, et al (1975) Generator-produced99mTc-TcO4 −: carrier free? J Nucl Med 16:639–641
Lenaz L, Page J (1976) Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Rev 3:111–120
Lewis A, Crouse V, Evans W, et al (1976) Recovery of left ventricular function following discontinuation of Adriamycin cardiotoxicity in children. Cancer Treat Rep 60:1281–1284
Lieberman M, Manasek FJ, Swanobori T, Johnson EA (1973) Cytochalasin B: its morphological and electrophysiological actions on synthetic strands of cardiac muscle. Dev Biol 31:380–403
Lipshultz SE, Golan SD, Gelber RD, et al (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815
Lobaugh LA (1985) Regulation of Na,K pump activity in cultured chick embryo heart cells. Ph. D. Thesis, Duke University, Durham, North Carolina
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193:265–275
Mailer K, Petering D (1976) Inhibition of oxidative phosphorylation in tumor cells by Adriamycin. Biochem Pharmacol 25:2085–2089
Maral RJ, Jouane M (1981) Toxicology of daunorubicin in animals and man, Cancer Treat Rep 65 [suppl 5]: 9–18
Mason J, Bristow M, Billingham M, Daniels J (1978) Invasive and non-invasive methods of assessing Adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62:857–864
McKillop J, Bristow M, Coris M, et al (1983) Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106:1048–1052
Moore L, Landon EJ, Cooney DC (1977) Inhibition of the cardiac mitochondrial calcium pump by Adriamycin in vitro. Biochem Med 18:131–138
Muller M, Moser R, Cheneval D, Carafoli E (1985) Cardiolipin is the membrane receptor for mitochondrial creatine kinase. J Biol Chem 260:3839–3843
Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165–167
Newman R, Hacker M, Fagan M (1982) Adriamycin-mediated inhibition of creatine kinase binding to heart mitochondrial membrane. Biochem Pharmacol 31:109–111
Olson HM, Young DM, Prieur DJ, Leroy AF, Regan RL (1974) Electrolyte and morphologic alterations of myocardium in Adriamycin-treated rabbits. Am J Pathol 77:439–454
Olson R, Mushlin P (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypothesis. FASEB J 4:3076–3086
Olson R, Boerth R, Gerber J, Nies A (1981) Mechanism of Adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 29:1393–1401
Piwnica-Worms D, Kronauge JF, Holman BL, Davison A, Jones AG (1989) Comparative myocardial uptake characteristics of hexakis (alkylisonitrile) technetium(I) complexes: effects of lipophilicity. Invest Radiol 24:25–29
Piwnica-Worms D, Kronauge JF, Delmon L, Holman BL, Marsh JD, Jones AG (1990) Effect of metabolic inhibition on technetium-99m-MIBI kinetics in cultured chick myocardial cells. J Nucl Med 31:464–472
Piwnica-Worms D, Kronauge JF, Chiu ML (1990) Uptake and retention of hexakis (2-methoxy isobutyl isonitrile)technetium(I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 82:1826–1838
Piwnica-Worms D, Kronauge JF, Chiu ML (1991) Enhancement by tetraphenylborate of99mTc-MIBI uptake kinetics and accumulation in cultured chick heart cells. J Nucl Med 32:1992–1999
Piwnica-Worms D, Chiu ML, Kronauge JF (1992) Divergent kinetics of Tl-201 and Tc-99m-SESTAMIBI in cultured chick ventricular myocytes during ATP depletion. Circulation 85:1531–1541
Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977–984
Palmeri ST, Bonow RO, Myers CE, et al (1986) Prospective evaluation of doxorubiein cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 58:607–613
Robison TW, Giri SN (1987) Effects of chronic administration of doxorubicin on heart phospholipase A2 activity and in vitro synthesis and degredation of prostaglandins in rats. Prostaglandins Leukotrienes Med 26:59–74
Rocco TP, Dilsizian V, Strauss HW, Boucher CA (1989) Technetium-99m-isonitrile myocardial uptake at rest: II. Relation to clinical markers of potential viability. J Am Coll Cardiol 14:1678–1684
Seraydarian M, Nagineni C (1987) Adriamycin toxicity in heart cells in culture. In: Pinson A (ed) The heart cell in culture, vol III CRC Press, Boca Raton, Florida, pp 19–34
Seraydarian MW, Luz A, Goodman MF (1977) Adriamycin: effect on mammalian cardiac cells in culture: I. Cell population and energy metabolism. J Mol Cardiol 9:375–382
Singal P, Deally C, Weinberg L (1987) Subcellular effects of Adriamycin in the heart: a concise review. J Mol Cell Cardiol 19:817–828
Sinusas AJ, Trautman KA, Bergin JD, et al (1990) Quantification of area at risk during coronary occlusion and degree of myocardial salvage after reperfusion with Tc-99m methoxyisobutylisonitrile. Circulation 82:1424–1437
Speth P, Hesel Q van, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15–31
Tosti FM, Bristow MR, Howes AE, et al (1983) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endocardial biopsy. Ann Intern Med 99:745–749
Tritton T (1991) Cell surface actions of Adriamycin. Pharmacol Ther 49:293–309
Wacker FJT, Berman D, Maddahi J, et al (1989) Tc-99m-hexakis 2-methoxy isobutylisonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 30:301–311
Wader S, Fuks J, Wiernik P (1986) Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol 26:491–509
Wakasugi S, Wada A, Hasegawa Y, Nakano S, Shibata N (1992) Detection of abnormal cardiac adrenergie neuron activity in Adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzyl-guanidine. J Nucl Med 33:208–214
Winterbourn C, Vile G, Monteiro H (1991) Ferritin, lipid peroxidation and redox-cycling xenobiotics. Free Radicals Res Commun 12/13:107–114
Young C, Raymond V (1986) Clinical assessment of the structureactivity relationship of anthracyclines and related synthetic derivatives. Cancer Treat Rep 70:51–63
Zahringer J, Hofling B, Raum W, Randolph R (1980) Effect of Adriamycin on the polyribosome and messenger-RNA content of rat heart muscle. Biochim Biophys Acta 608:315–323
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Piwnica-Worms, D., Chiu, M.L. & Kronauge, J.F. Detection of Adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI. Cancer Chemother. Pharmacol. 32, 385–391 (1993). https://doi.org/10.1007/BF00735924
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00735924